Genomma Lab EBITDA vs. Current Valuation
| LABB Stock | MXN 25.78 0.27 1.06% |
For Genomma Lab profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Genomma Lab to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Genomma Lab Internacional utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Genomma Lab's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Genomma Lab Internacional over time as well as its relative position and ranking within its peers.
Genomma |
Genomma Lab Internacional Current Valuation vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Genomma Lab's current stock value. Our valuation model uses many indicators to compare Genomma Lab value to that of its competitors to determine the firm's financial worth. Genomma Lab Internacional is currently regarded as number one stock in ebitda category among its peers. It also is considered the number one company in current valuation category among its peers reporting about 7.20 of Current Valuation per EBITDA. Comparative valuation analysis is a catch-all model that can be used if you cannot value Genomma Lab by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Genomma Lab's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Genomma Current Valuation vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Genomma Lab |
| = | 2.84 B |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Genomma Lab |
| = | 20.43 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Genomma Current Valuation vs Competition
Genomma Lab Internacional is considered the number one company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 1.89 Trillion. Genomma Lab claims roughly 20.43 Billion in current valuation contributing just under 2% to equities under Health Care industry.
Genomma Lab Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Genomma Lab, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Genomma Lab will eventually generate negative long term returns. The profitability progress is the general direction of Genomma Lab's change in net profit over the period of time. It can combine multiple indicators of Genomma Lab, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Genomma Lab Internacional, S.A.B. de C.V. together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico, the United States, and Latin America. Genomma Lab Internacional, S.A.B. de C.V. was founded in 1996 and is based in Mexico City, Mexico. GENOMMA LAB operates under Drug ManufacturersSpecialty Generic classification in Mexico and is traded on Mexico Stock Exchange. It employs 1451 people.
Genomma Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Genomma Lab. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Genomma Lab position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Genomma Lab's important profitability drivers and their relationship over time.
Use Genomma Lab in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Genomma Lab position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genomma Lab will appreciate offsetting losses from the drop in the long position's value.Genomma Lab Pair Trading
Genomma Lab Internacional Pair Trading Analysis
The ability to find closely correlated positions to Genomma Lab could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Genomma Lab when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Genomma Lab - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Genomma Lab Internacional to buy it.
The correlation of Genomma Lab is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Genomma Lab moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Genomma Lab Internacional moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Genomma Lab can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Genomma Lab position
In addition to having Genomma Lab in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Printing and Publishing Thematic Idea Now
Printing and Publishing
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Printing and Publishing theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Printing and Publishing Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Genomma Stock Analysis
When running Genomma Lab's price analysis, check to measure Genomma Lab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genomma Lab is operating at the current time. Most of Genomma Lab's value examination focuses on studying past and present price action to predict the probability of Genomma Lab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genomma Lab's price. Additionally, you may evaluate how the addition of Genomma Lab to your portfolios can decrease your overall portfolio volatility.